You searched for "AMD"
Treat-and-extend regimen in treatment of patients with type 3 neovascularisation
Type 3 neovascularisation, also known as retinal angiomatous proliferation is a distinct subtype of neovascular AMD characterised by intraretinal neovascularisation. This retrospective study included 17 eyes diagnosed with type 3 neovascularisation who were changed from pro-re-nata (PRN) based treatment regime...
Intravitreal Ziv-Aflibercept: safety analysis
Ziv-Aflibercept (Zaltrap; Sanofi-Aventis U.S LLS, Bridgewater, NJ) was originally introduced as an intravenous formulation for metastatic colorectal cancer. The adoption of Ziv-Aflibercept in ophthalmic practice was similar to bevacizumab, and reports have previously examined one to two year visual outcomes...The meaning of life
Supercomputer: “The answer to the great question of Life, the Universe and Everything is…”Programmer: “Yes…?”Supercomputer: “42. It was a tough assignment”.Programmer: “42? Is that all you have got to show for seven and a half million years work?” In this...Conference Report: ARVO 2025 Annual Meeting
The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting was held at the Salt Palace Convention Centre in Salt Lake City, US. This prestigious event brought together experts in vision and ophthalmology from around the world for...Coming to terms with AI
A machine might be called intelligent if its response to questions could convince a person that it was human, a test proposed by Alan Turing in 1950 [1]. The author considers potential applications of artificial intelligence (AI) using machine learning...High quality retinal image grading and management service by the NetwORC UK
In 2004 a network of three ophthalmic reading centres in Belfast, London and Liverpool (known as NetwORC UK) was established to form the largest reading centre in Europe for the purpose of providing high quality grading of ophthalmic images for...Intravitreal injections delivered by ophthalmic clinical nurse specialists
Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...
